| 摘要 |
According to the present invention we provide a pharmaceutical aerosol formulation, comprising a hydrofluoroalkane (HFA) propellant having dissolved therein (2R,3R,4S,5R)-2-[6-Amino-2-(1S-hydroxymethyl-2-phenyl-ethylamino)-purin-9-yl]-5-(2-ethyl-2H-tetrazol-5-yl)-tetrahydro-furan-3,4-diol or a salt or solvate thereof. |
